CISPLATIN AND VINDESINE COMBINATION CHEMOTHERAPY FOR ADVANCED-CARCINOMA OF THE LUNG - A RANDOMIZED TRIAL INVESTIGATING 2 DOSAGE SCHEDULES
CISPLATIN AND VINDESINE COMBINATION CHEMOTHERAPY FOR ADVANCED-CARCINOMA OF THE LUNG - A RANDOMIZED TRIAL INVESTIGATING 2 DOSAGE SCHEDULES
复制标题
DOI：
10.7326/0003-4819-95-4-414
复制
发表时间：
1981-01-01
影响因子：
39.2
通讯作者：
GOLBEY, RB
中科院分区：
文献类型：
--
作者：
GRALLA, RJ;CASPER, ES;GOLBEY, RB
晚期肺鳞癌或腺癌患者（85例）被随机分配接受高剂量（120 mg/m2体表面积）或低剂量（60 mg/m2）顺铂长春地辛治疗。所有患者都有可测量的疾病，以前没有接受过化疗。两种治疗的反应率相似（43%完全和部分缓解率），但高剂量顺铂方案在中位反应持续时间方面上级低剂量方案（12个月对5.5个月; P = 0.05）和缓解患者的中位生存期（21.7 vs. 10个月; P = 0.02）。骨髓抑制通常不是治疗问题;周围神经病变和中度氮质血症是主要的剂量限制性毒性。与传统方案相比，新药物的组合提高了生存率和缓解率，支持肺癌患者的新药研究方法，以及将活性新药纳入初始化疗方案的重要性。
Patients (85) with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with high dose (120 mg/m2 of body surface area) or low dose (60 mg/m2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43% complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 vs. 5.5 mo.; P = 0.05) and in median survival for responding patients (21.7 vs. 10 mo.; P = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer, and the importance of the incorporation of active new agents into initial chemotherapy regimens.